From 3a20ab8c32eb129089e46d014974c1145c9febf8 Mon Sep 17 00:00:00 2001 From: marius-mather Date: Mon, 30 Sep 2024 14:17:54 +1000 Subject: [PATCH] Update about page --- app/about/AboutContent.mdx | 83 ++++++++++++++++++-------------------- app/about/page.tsx | 5 ++- 2 files changed, 43 insertions(+), 45 deletions(-) diff --git a/app/about/AboutContent.mdx b/app/about/AboutContent.mdx index 948c9e6..53dadc9 100644 --- a/app/about/AboutContent.mdx +++ b/app/about/AboutContent.mdx @@ -1,56 +1,51 @@ - -This tool, developed by the FRONTIER Research Group at the -University of Sydney, is designed to assist clinicians in -screening patients for dementia. +This tool, developed by the FRONTIER Research Group at the University of +Sydney, is designed to assist clinicians in screening patients for +dementia. ### Clinician Notice This tool is intended for use only by clinicians trained in -administering and interpreting the ACE-III. It is a screening -tool, not a diagnostic instrument, and provides a risk score to -guide further diagnostic evaluations. It does not diagnose -dementia. +administering and interpreting the ACE-III. It is a screening tool, not +a diagnostic instrument, and provides a risk score to guide further +diagnostic evaluations. It does not diagnose dementia. ### About FRONTIER -The FRONTIER Research Group, based at the Brain and Mind Centre, -University of Sydney, specialises in the study of younger-onset -dementias. Patients in the FRONTIER programme are typically -assessed every 12 months until discontinuation. Assessments -typically include a comprehensive neurological exam, a -neuropsychological evaluation, and a structural brain MRI, -completed within a 3-month period. For more information on -FRONTIER assessment procedures, visit [https://osf.io/6hpax/](https://osf.io/6hpax/). +FRONTIER is based at the Brain and Mind Centre, University of Sydney, +and specialises in the study of younger-onset dementias. Patients in the +FRONTIER research programme are typically assessed every 12 months until +discontinuation. Assessments typically include a comprehensive +neurological examination, a neuropsychological assessment, and a +structural brain MRI, completed within a 3-month period. For more +information on FRONTIER assessment procedures, visit [https://osf.io/6hpax/](https://osf.io/6hpax/). ### About the Dataset -This case-control study included participants recruited from -September 2011 to December 2023. It comprises 431 patients with -dementia (409 with a major neurocognitive disorder and 22 with a -minor neurocognitive disorder at the last clinical assessment) and -107 non-dementia controls. - -The dataset includes annual repeat -assessments, resulting in 844 ACE-III assessments from patients -with dementia (789 with a major and 55 with a minor neurocognitive -disorder) and 224 ACE-III assessments from non-dementia controls. -This dataset is based on performance profiles from the Australian -version of the ACE-III. The dementia risk value is derived from a -binomial logistic regression model. For more information about the -dataset and model, visit [https://osf.io/6hpax/](https://osf.io/6hpax/). - -### Financial support - -This tool was developed with support from the Edwards Fund for -Dementia Research at the Brain and Mind Centre, University of -Sydney. Contact For questions about the ACE-III Online Dementia -Screening Tool, please contact FRONTIER at [frontier@sydney.edu.au](mailto:frontier@sydney.edu.au). -To learn more about the ACE-III or download the test and -administration guide, visit [https://frontierftd.org](https://frontierftd.org). +This case-control study included participants recruited from September +2011 to December 2023. It comprises 431 patients with dementia (409 with +a major neurocognitive disorder and 22 with a minor neurocognitive +disorder at the last clinical assessment) and 107 non-dementia controls. + +The dataset includes annual repeat assessments, resulting in 844 ACE-III +assessments from patients with dementia (789 with a major and 55 with a +minor neurocognitive disorder) and 224 ACE-III assessments from +non-dementia controls. This dataset is based on performance profiles +from the Australian version of the ACE-III. The dementia risk value is +derived from a binomial logistic regression model. For more information +about the dataset and model, visit [https://osf.io/6hpax/](https://osf.io/6hpax/). + +### Financial Support + +This tool was developed with support from the Edwards Fund for Dementia +Research and the Steven Warman Research Fund in Frontotemporal Dementia +at the Brain and Mind Centre, University of Sydney. This tool was also +supported in part by funding from the National Health and Medical +Research Council (NHMRC) (GNT1037746, GNT2024329, GNT2025228, +GNT2008020) and the Australian Research Council (ARC) Centre of +Excellence in Cognition and its Disorders Memory Program (CE11000102). ### Contact -For questions about the ACE-III Online Dementia Screening Tool, -please contact FRONTIER at -[frontier@sydney.edu.au](mailto:frontier@sydney.edu.au). -To learn more about the ACE-III or download the test and -administration guide, visit [https://frontierftd.org](https://frontierftd.org). \ No newline at end of file + +For questions about the ACE-III Online Dementia Screening Tool, please +contact FRONTIER at [frontier@sydney.edu.au](frontier@sydney.edu.au). To learn more about the +ACE-III or download the test and administration guide, visit [https://frontierftd.org](https://frontierftd.org). diff --git a/app/about/page.tsx b/app/about/page.tsx index 3b7b438..f50cc1a 100644 --- a/app/about/page.tsx +++ b/app/about/page.tsx @@ -15,7 +15,10 @@ export default function About() { return (
- +

Welcome to the Addenbrooke’s Cognitive Examination-III (ACE-III)